The presence of BRAF or KRAS mutation had no significant effect on PFS and OS in the Keynote 177 trial of pembrolizumab compared to chemotherapy in MSI-H advanced colorectal cancer [77,78]. This evidence concerns the gene KRAS and colorectal cancer.